stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) Free cash flow
Neurocrine Biosciences, Inc.'s free cash flow for fiscal 2025 was $748.7M, up 34.4% from $557.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.0B. Over the past ten years it has ranged from −$110.3M (fiscal 2016) to $748.7M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 9 consecutive fiscal years. Neurocrine Biosciences, Inc. ranks 6th of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $748.7M | 34.37% |
| FY2024 | $557.2M | 54.09% |
| FY2023 | $361.6M | 11.99% |
| FY2022 | $322.9M | 38.52% |
| FY2021 | $233.1M | 7.12% |
| FY2020 | $217.6M | 64.47% |
| FY2019 | $132.3M | 72.72% |
| FY2018 | $76.6M | — |
| FY2017 | −$101.3M | — |
| FY2016 | −$110.3M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $383.6M | 198.29% |
| Jun 2026 | $128.6M | (5.93%) |
| Mar 2026 | $136.7M | (65.02%) |
| Dec 2025 | $390.8M | 82.36% |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $4.6B |
| VTRS Viatris Inc. compare | $2.4B |
| ZTS Zoetis Inc. compare | $2.3B |
| NBIX Neurocrine Biosciences, Inc. | $1.0B |
| UTHR United Therapeutics Corporation compare | $867.2M |
| ELAN Elanco Animal Health Incorporated compare | $379.0M |
| ALKS Alkermes plc compare | $228.4M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $197.2M |
| RDY Dr. Reddy's Laboratories Ltd compare | $96.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on NBIX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement